Patents whose numbers are in italics have been extended under 35 USC 156. Unless otherwise noted, all expiration dates include applicable Sec. 156 and pediatric (PED) extensions.
Pat No. Expir. Patent Title, Tradenames & Claim Types 6716602 Nov 1, 2021 Metabolic rate shifts in fermentations expressing recombinant proteins
Claim Types: Process
Lucentis (Injection) (Intravitreal)6805686 May 6, 2023 Autoinjector with extendable needle protector shroud
Claim Types: Device; Method of administration
Humira (Injection) (Subcutaneous)6828121 Jul 8, 2022 Bacterial host strains
Claim Types: Bacterial strain; Process
Lucentis (Injection) (Intravitreal)6902734 Sep 25, 2023 Anti-IL-12 antibodies and compositions thereof
Claim Types: Compound; Composition
Stelara (Injection) (Subcutaneous); Stelara (Injection) (Intravenous)6921659 Oct 17, 2023 Protease-deficient cells
Claim Types: Bacterial strain; Process
Lucentis (Injection) (Intravitreal)7070959 Jun 16, 2023 Modified chimeric polypeptides with improved pharmacokinetic properties
Claim Types: Nucleic Acid; Expression Vector; Process
Eylea (Injection) (Intravitreal)7157276 Jun 21, 2024 Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
Claim Types: Process
Tysabri (Injection) (Intravenous)7332289 Aug 4, 2023 Method of purifying protein
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)7364736 Feb 19, 2025 Antibodies to OPGL
Claim Types: Compound; Composition
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)7427659 Mar 15, 2025 Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)7485704 Mar 8, 2025 Reducing protein A leaching during protein A affinity chromatography
Claim Types: Process
Avastin (Injection) (Intravenous)7521052 Apr 28, 2024 Methods for treating interleukin-6 related diseases
Claim Types: Method of use
Actemra () (); Actemra (Injection) (Intravenous)7759117 Jun 21, 2024 Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
Claim Types: Process
Tysabri (Injection) (Intravenous)7928205 Feb 12, 2027 Methods for refolding of recombinant antibodies
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)8058418 Nov 30, 2023 Polynucleotides encoding heavy and light chains of antibodies to OPGL
Claim Types: Formulation
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)8124350 Aug 2, 2027 Methods and products for evaluating an immune response to a therapeutic protein
Claim Types: Diagnostic or surgical method
Tysabri (Injection) (Intravenous)8231876 Apr 4, 2027 Purified antibody composition
Claim Types: Product-by-process; Drug in a container
Humira (Injection) (Subcutaneous)8318416 Jan 20, 2031 Nutrient monitoring and feedback control for increased bioproduct production
Claim Types: Process
Tysabri (Injection) (Intravenous)8383773 Dec 13, 2023 Protein product and method for reducing biomass-biomass interactions
Claim Types: Product-by-process
Lucentis (Injection) (Intravitreal)8398980 Sep 27, 2026 Subtypes of humanized antibody against interleuken-6 receptor
Claim Types: Compound; Composition
Actemra () (); Actemra (Injection) (Intravenous)8420081 Jan 13, 2030 Antibody formulations and methods of making same
Claim Types: Formulation; Product-by-process; Device; Drug in a container; Process
Humira (Injection) (Subcutaneous)8460895 Mar 11, 2029 Method for producing recombinant proteins with a constant content of pCO.sub.2 in the medium
Claim Types: Process
Avastin (Injection) (Intravenous)8512983 Jan 4, 2031 Production of proteins in glutamine-free cell culture media
Claim Types: Process; Cell culture medium
Avastin (Injection) (Intravenous)8512983 Jan 9, 2030 Production of proteins in glutamine-free cell culture media
Claim Types: Process; Cell culture medium
Actemra () (); Actemra (Injection) (Intravenous)8568720 Nov 5, 2029 High concentration antibody-containing liquid formulation
Claim Types: Formulation
Actemra () (); Actemra (Injection) (Intravenous)8574869 Jul 8, 2028 Prevention of disulfide bond reduction during recombinant production of polypeptides
Claim Types: Process
Herceptin (For Injection) (Intravenous); Avastin (Injection) (Intravenous); Lucentis (Injection) (Intravitreal)8574869 Jul 9, 2027 Prevention of disulfide bond reduction during recombinant production of polypeptides
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)8580264 Nov 8, 2030 Subcutaneously administered anti-IL-6 receptor antibody
Claim Types: Method of use
Actemra () (); Actemra (Injection) (Intravenous)8617550 Sep 11, 2025 Treatment of vasculitis with IL-6 antagonist
Claim Types: Method of use
Actemra () (); Actemra (Injection) (Intravenous)8663945 Sep 13, 2027 Methods of producing anti-TNF-alpha antibodies in mammalian cell culture
Claim Types: Process
Humira (Injection) (Subcutaneous)8708968 Jan 24, 2032 Removal of needle shields from syringes and automatic injection devices
Claim Types: Device
Humira (Injection) (Subcutaneous)8709409 Jun 22, 2024 Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate
Claim Types: Method of use
Actemra () (); Actemra (Injection) (Intravenous)8715664 Jul 24, 2027 Use of human TNF.alpha. antibodies for treatment of erosive polyarthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8734800 Mar 24, 2025 Subtypes of humanized antibody against interleukin-6 receptor
Claim Types: Method of use
Actemra () (); Actemra (Injection) (Intravenous)8808700 May 16, 2026 Use of TNF alpha inhibitor for treatment of erosive polyarthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8809049 May 22, 2031 Methods for producing mammalian cells
Claim Types: Process
Tysabri (Injection) (Intravenous)8852889 Jul 6, 2032 Cell culture process
Claim Types: Process
Stelara (Injection) (Subcutaneous); Stelara (Injection) (Intravenous)8871449 Apr 12, 2026 Methods and products for evaluating an immune response to a therapeutic protein
Claim Types: Diagnostic or surgical method
Tysabri (Injection) (Intravenous)8883156 Apr 4, 2027 Purified antibody composition
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8889136 Oct 9, 2027 Multiple-variable dose regimen for treating TNF.alpha.-related disorders
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)8895009 Apr 4, 2027 Purified antibody composition
Claim Types: Formulation
Humira (Injection) (Subcutaneous)8906372 Apr 4, 2027 Purified antibody composition
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8906373 Jul 18, 2023 Use of TNF-alpha inhibitor for treatment of psoriasis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8906646 Sep 13, 2027 Fed-batch method of making human anti-TNF-alpha antibody
Claim Types: Process
Humira (Injection) (Subcutaneous)8911737 Jun 5, 2022 Methods of administering anti-TNF.alpha. antibodies
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8911964 Sep 13, 2027 Fed-batch method of making human anti-TNF-alpha antibody
Claim Types: Process
Humira (Injection) (Subcutaneous)8916153 Apr 4, 2027 Purified antibody composition
Claim Types: Composition
Humira (Injection) (Subcutaneous)8926975 Jun 8, 2027 Method of treating ankylosing spondylitis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)8961973 Apr 11, 2025 Multiple-variable dose regimen for treating TNF.alpha.-related disorders
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)8961974 Apr 11, 2025 Multiple-variable dose regimen for treating TNF.alpha.-related disorders
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)8974790 Jun 5, 2022 Methods of administering anti-TNF.alpha. antibodies
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)8986693 Apr 11, 2025 Use of TNF.alpha. inhibitor for treatment of psoriasis
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)8992926 Jun 5, 2022 Methods of administering anti-TNF.alpha. antibodies
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)8999337 Feb 6, 2031 Methods for treating juvenile idiopathic arthritis by inhibition of TNF.alpha.
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9005926 Oct 1, 2030 Methods of preventing and removing trisulfide bonds
Claim Types: Process
Tysabri (Injection) (Intravenous)9012178 Aug 5, 2031 Dipeptides to enhance yield and viability from cell cultures
Claim Types: Process; Cell culture
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)9061005 Apr 11, 2025 Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)9062106 Apr 26, 2032 Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Claim Types: Process
Humira (Injection) (Subcutaneous)9067992 Jul 18, 2023 Use of TNF.alpha. inhibitor for treatment of psoriatic arthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9085618 Mar 14, 2033 Low acidic species compositions and methods for producing and using the same
Claim Types: Formulation; Method of use
Humira (Injection) (Subcutaneous)9085619 Nov 28, 2028 Anti-TNF antibody formulations
Claim Types: Composition; Formulation
Humira (Injection) (Subcutaneous)9085620 Jul 18, 2023 Use of TNF.alpha. inhibitor for treatment of psoriatic arthritis
Claim Types: Method of administration; Process
Humira (Injection) (Subcutaneous)9090688 Apr 26, 2032 Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Claim Types: Process
Humira (Injection) (Subcutaneous)9090689 Jul 18, 2023 Use of TNF.alpha. inhibitor for treatment of psoriasis
Claim Types: Method of administration; Process
Humira (Injection) (Subcutaneous)9090867 Sep 13, 2027 Fed-batch method of making anti-TNF-alpha antibody
Claim Types: Process
Humira (Injection) (Subcutaneous)9096666 Apr 4, 2027 Purified antibody composition
Claim Types: Formulation
Humira (Injection) (Subcutaneous)9096879 Jan 7, 2031 Method of supplementing culture media to prevent undesirable amino acid substitutions
Claim Types: Process
Tysabri (Injection) (Intravenous)9102723 Apr 4, 2027 Purified antibody composition
Claim Types: Process; Product-by-process; Method of use
Humira (Injection) (Subcutaneous)9109015 Aug 13, 2031 Method of isolating biomacromolecules using low pH and divalent cations
Claim Types: Process
Tysabri (Injection) (Intravenous)9133493 Apr 20, 2032 Method for culturing mammalian cells to improve recombinant protein production
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)9150645 May 13, 2033 Cell culture methods to reduce acidic species
Claim Types: Process
Humira (Injection) (Subcutaneous)9181337 Mar 14, 2033 Modulated lysine variant species compositions and methods for producing and using the same
Claim Types: Formulation
Humira (Injection) (Subcutaneous)9181572 Mar 14, 2033 Methods to modulate lysine variant distribution
Claim Types: Process
Humira (Injection) (Subcutaneous)9187559 Apr 11, 2025 Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
Claim Types: Dosaage regimen
Humira (Injection) (Subcutaneous)9212379 Nov 28, 2030 Nutrient monitoring and feedback control for increased bioproduct production
Claim Types: Process
Tysabri (Injection) (Intravenous)9217168 Mar 14, 2033 Methods of cell culture
Claim Types: Process
Stelara (Injection) (Subcutaneous); Stelara (Injection) (Intravenous)9222106 Jun 4, 2028 Enhanced expression and stability regions
Claim Types: Cell; Process
Eylea (Injection) (Intravitreal)9228168 Jan 19, 2030 Feed media
Claim Types: Process; Cell culture medium
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)9234032 Sep 13, 2027 Fed-batch methods for producing adalimumab
Claim Types: Process
Humira (Injection) (Subcutaneous)9254338 May 22, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)9266949 May 13, 2033 Low acidic species compositions and methods for producing and using the same
Claim Types: Process
Humira (Injection) (Subcutaneous)9273132 Apr 4, 2027 Purified antibody composition
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9284370 Jun 10, 2028 Methods for treating juvenile idiopathic arthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9284371 Sep 13, 2027 Methods of producing adalimumab
Claim Types: Process
Humira (Injection) (Subcutaneous)9290568 Mar 14, 2033 Methods to control protein heterogeneity
Claim Types: Process
Humira (Injection) (Subcutaneous)9315574 Apr 21, 2033 Low acidic species compositions and methods for producing and using the same
Claim Types: Process
Humira (Injection) (Subcutaneous)9316641 Jan 9, 2032 Assay for JC virus antibodies
Claim Types: Diagnostic or surgical method
Tysabri (Injection) (Intravenous)9320816 Nov 14, 2030 Methods of treating cell culture media for use in a bioreactor
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)9328134 Feb 20, 2034 Carbohydrate phosphonate derivatives as modulators of glycosylation
Claim Types: Compound; Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)9328165 Apr 4, 2027 Purified antibody composition
Claim Types: Formulation
Humira (Injection) (Subcutaneous)9334319 Mar 14, 2033 Low acidic species compositions
Claim Types: Formulation claimed by its inherent performace characteristics
Humira (Injection) (Subcutaneous)9339610 Jan 24, 2032 Removal of needle shield from syringes and automatic injection devices
Claim Types: Device
Humira (Injection) (Subcutaneous)9346879 Mar 14, 2033 Protein purification methods to reduce acidic species
Claim Types: Process
Humira (Injection) (Subcutaneous)9359434 Mar 14, 2033 Cell culture methods to reduce acidic species
Claim Types: Process
Humira (Injection) (Subcutaneous)9359435 May 22, 2027 Methods for modulating mannose content of recombinant proteins
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)9388447 Apr 20, 2032 Method for culturing mammalian cells to improve recombinant protein production
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)9441035 Apr 23, 2034 Cell culture media and methods of antibody production
Claim Types: Process
Avastin (Injection) (Intravenous)9475858 Jul 6, 2032 Cell culture process
Claim Types: Process
Stelara (Injection) (Subcutaneous); Stelara (Injection) (Intravenous)9481901 May 29, 2034 Methods for increasing mannose content of recombinant proteins
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)9487809 Jan 14, 2032 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
Claim Types: Process
Avastin (Injection) (Intravenous)9493567 Mar 5, 2027 Methods of treating inflammatory and autoimmune diseases with natalizumab
Claim Types: Method of use
Tysabri (Injection) (Intravenous)9499614 Mar 14, 2034 Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
Claim Types: Process
Humira (Injection) (Subcutaneous)9499616 Mar 14, 2033 Modulated lysine variant species compositions and methods for producing and using the same
Claim Types: Process
Humira (Injection) (Subcutaneous)9505834 Apr 26, 2032 Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Claim Types: Process
Humira (Injection) (Subcutaneous)9512216 Apr 11, 2025 Use of TNF.alpha. inhibitor
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9522953 Apr 26, 2032 Low acidic species compositions and methods for producing and using the same
Claim Types: Drug in a container; Method of use
Humira (Injection) (Subcutaneous)9539263 Nov 8, 2030 Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis
Claim Types: Method of use
Actemra () (); Actemra (Injection) (Intravenous)9546212 Jun 5, 2022 Methods of administering anti-TNF.alpha. antibodies
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9550826 Nov 14, 2034 Glycoengineered binding protein compositions
Claim Types: Formulation
Humira (Injection) (Subcutaneous)9562252 May 11, 2033 Methods of preventing and removing trisulfide bonds
Claim Types: Process
Tysabri (Injection) (Intravenous)9624295 Mar 31, 2031 Uses and compositions for treatment of psoriatic arthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9630988 Jun 13, 2032 Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)9663810 Mar 14, 2033 Methods of cell culture
Claim Types: Process
Stelara (Injection) (Subcutaneous); Stelara (Injection) (Intravenous)9669069 Jan 11, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)9669093 Jun 10, 2028 Methods for treating juvenile idiopathic arthritis
Claim Types: Method of use
Humira (Injection) (Subcutaneous)9683033 Apr 26, 2032 Cell culture methods to reduce acidic species
Claim Types: Formulation; Method of use
Humira (Injection) (Subcutaneous)9688775 Dec 31, 2022 System for antibody expression and assembly
Claim Types: Process
Lucentis (Injection) (Intravitreal)9696307 Feb 5, 2030 Methods for the detection of JC polyoma virus
Claim Types: Diagnostic or surgical method
Tysabri (Injection) (Intravenous)9708400 Mar 14, 2033 Methods to modulate lysine variant distribution
Claim Types: Formulation
Humira (Injection) (Subcutaneous)9709575 Apr 4, 2026 Methods and products for evaluating an immune response to a therapeutic protein
Claim Types: Diagnostic or surgical method
Tysabri (Injection) (Intravenous)9714293 Aug 6, 2030 Production of proteins in glutamine-free cell culture media
Claim Types: Process
Avastin (Injection) (Intravenous)9714293 Jan 9, 2030 Production of proteins in glutamine-free cell culture media
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)9750752 Sep 1, 2031 Subcutaneously administered anti-IL-6 receptor antibody
Claim Types: Method of use
Actemra () (); Actemra (Injection) (Intravenous)9765379 Mar 10, 2034 Harvest operations for recombinant proteins
Claim Types: Process
Lucentis (Injection) (Intravitreal)9790533 May 11, 2032 Methods of preventing and removing trisulfide bonds
Claim Types: Cell culture
Tysabri (Injection) (Intravenous)9795672 May 28, 2024 Treatment with anti-VEGF antibodies
Claim Types: Method of use
Avastin (Injection) (Intravenous)9816110 Oct 21, 2035 CHO integration sites and uses thereof
Claim Types: Cell; Process
Eylea (Injection) (Intravitreal)9856287 Jun 21, 2030 Refolding proteins using a chemically controlled redox state
Claim Types: Process
Neulasta (Injection) (Subcutaneous); Neulasta Onpro (Injection) (Subcutaneous)9902777 May 28, 2025 Methods for producing subtypes of humanized antibody against interleukin-6 receptor
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)9913902 Apr 4, 2027 Purified antibody composition
Claim Types: Formulation claimed by its inherent performace characteristics
Humira (Injection) (Subcutaneous)9957318 Apr 26, 2032 Protein purification methods to reduce acidic species
Claim Types: Process
Humira (Injection) (Subcutaneous)9994968 Aug 19, 2034 Electrochemical etching apparatus
Claim Types: Process
Tysabri (Injection) (Intravenous)10011856 May 26, 2031 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
Claim Types: Cell culture
Avastin (Injection) (Intravenous)10017732 Mar 14, 2034 Cell culture compositions with antioxidants and methods for polypeptide production
Claim Types: Process
Avastin (Injection) (Intravenous); Lucentis (Injection) (Intravitreal)10017732 Mar 15, 2033 Cell culture compositions with antioxidants and methods for polypeptide production
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)10023831 Mar 17, 2035 Gas delivery devices and associated systems and methods
Claim Types: Device
Tysabri (Injection) (Intravenous)10112994 Nov 5, 2035 Methods of producing two chain proteins in bacteria
Claim Types: Process
Lucentis (Injection) (Intravitreal)10119976 May 27, 2034 Method of assessing risk of PML
Claim Types: Diagnostic or surgical method; Method of use
Tysabri (Injection) (Intravenous)10130681 Jan 11, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)10167492 Dec 1, 2035 Process for manipulating the level of glycan content of a glycoprotein
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)10208355 Jul 14, 2035 Method of treatment for glioblastoma by administering a VEGF antagonist
Claim Types: Method of use
Avastin (Injection) (Intravenous)10231981 Nov 19, 2030 Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis
Claim Types: Method of use
Actemra () (); Actemra (Injection) (Intravenous)10233245 Feb 28, 2027 Methods of treating inflammatory and autoimmune diseases with natalizumab
Claim Types: Method of use
Tysabri (Injection) (Intravenous)10274466 Jul 11, 2035 Elucidation of ion exchange chromatography input optimization
Claim Types: Analytical procedure
Avastin (Injection) (Intravenous)10308706 Feb 5, 2031 Methods of preventing and removing trisulfide bonds
Claim Types: Process
Tysabri (Injection) (Intravenous)10336983 Jul 31, 2035 Method for increasing the specific production rate of eukaryotic cells
Claim Types: Process
Avastin (Injection) (Intravenous); Actemra () (); Actemra (Injection) (Intravenous)10406226 Mar 22, 2026 Method of manufacturing VEGF antagonist fusion proteins
Claim Types: Process
Eylea (Injection) (Intravitreal)10415055 Jun 4, 2028 Enhanced expression and stability regions
Claim Types: Cell; Process
Eylea (Injection) (Intravitreal)10421984 Sep 19, 2033 Methods for reducing norleucine misincorporation into proteins using a microorganism comprising a mutant metA allele
Claim Types: Process
Lucentis (Injection) (Intravitreal)10444234 Jan 11, 2031 Assay for JC virus antibodies
Claim Types: Diagnostic or surgical method; Device
Tysabri (Injection) (Intravenous)10464992 Jun 14, 2027 VEGF antagonist formulations suitable for intravitreal administration
Claim Types: Drug in a container; Formulation
Eylea (Injection) (Intravitreal)10501769 Oct 25, 2030 Method for the production of a glycosylated immunoglobulin
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)10513697 Sep 17, 2032 CO.sub.2 profile cultivation
Claim Types: Process
Avastin (Injection) (Intravenous)10513723 Dec 9, 2034 Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)10583397 Jul 28, 2035 Process control systems and methods for use with filters and filtration processes
Claim Types: Device
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)10590164 Mar 19, 2032 Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)10590454 May 11, 2032 Methods of preventing and removing trisulfide bonds
Claim Types: Process
Tysabri (Injection) (Intravenous)10662237 May 26, 2030 Method to improve virus filtration capacity
Claim Types: Process
Herceptin (For Injection) (Intravenous); Actemra () (); Actemra (Injection) (Intravenous)10662237 May 26, 2031 Method to improve virus filtration capacity
Claim Types: Process
Avastin (Injection) (Intravenous)10669594 Feb 12, 2037 Compositions and methods for detecting a biological contaminant
Claim Types: Analytical Method
Eylea (Injection) (Intravitreal)10676710 Mar 14, 2034 Cell culture compositions with antioxidants and methods for polypeptide production
Claim Types: Process
Avastin (Injection) (Intravenous)10676710 Mar 15, 2033 Cell culture compositions with antioxidants and methods for polypeptide production
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)10676772 Aug 19, 2034 Control of protein glycosylation by culture medium supplementation and cell culture process parameters
Claim Types: Process
Tysabri (Injection) (Intravenous)10677803 May 27, 2034 Method of assessing risk of PML
Claim Types: Method of use
Tysabri (Injection) (Intravenous)10704071 Aug 18, 2031 Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
Claim Types: Vector
Avastin (Injection) (Intravenous)10705095 Apr 4, 2026 Methods and products for evaluating an immune response to a therapeutic protein
Claim Types: Diagnostic or surgical method
Tysabri (Injection) (Intravenous)10744201 Apr 28, 2024 Method for treating rheumatoid arthritis with a human IL-6 receptor antibody and methotrexate
Claim Types: Method of improving a treatment
Actemra () (); Actemra (Injection) (Intravenous)10808037 Jul 8, 2028 Prevention of disulfide bond reduction during recombinant production of polypeptides
Claim Types: Process
Herceptin (For Injection) (Intravenous)10822630 Dec 1, 2035 Process for manipulating the level of glycan content of a glycoprotein
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)10828354 Jan 11, 2032 Laser-assisted intradermal administration of active substances
Claim Types: Method of use; Method of improving a treatment
Eylea (Injection) (Intravitreal)10829732 Mar 14, 2034 Cell culture compositions with antioxidants and methods for polypeptide production
Claim Types: Process
Avastin (Injection) (Intravenous); Lucentis (Injection) (Intravitreal)10829732 Mar 15, 2033 Cell culture compositions with antioxidants and methods for polypeptide production
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)10844416 Jun 1, 2036 Manganese supplementation for control of glycosylation in mammalian cell culture process
Claim Types: Process
Tysabri (Injection) (Intravenous)10857205 Jan 11, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)10857231 Disclaimer filed on March 14, 2022 Formulations of VEG antagonist fusion proteins and method of manufacturing them
Claim Types: Formulation; Formulation claimed by its inherent performace characteristics; Process
Eylea (Injection) (Intravitreal)10874677 Mar 4, 2031 Subcutaneously administered anti-IL-6 receptor antibody
Claim Types: Device
Actemra () (); Actemra (Injection) (Intravenous)10888601 Jan 11, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Dosaage regimen
Eylea (Injection) (Intravitreal)10894972 May 29, 2034 Methods for increasing mannose content of recombinant proteins
Claim Types: Cell culture medium; Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)10905786 Mar 6, 2038 Sterilisation method
Claim Types: Process
Eylea (Injection) (Intravitreal)10906934 Oct 12, 2033 Protein purification methods
Claim Types: Process
Avastin (Injection) (Intravenous)10906986 Jul 8, 2028 Prevention of disulfide bond reduction during recombinant production of polypeptides
Claim Types: Process
Avastin (Injection) (Intravenous)10918754 Mar 6, 2038 Sterilisation method
Claim Types: Process
Eylea (Injection) (Intravitreal)10927342 Aug 3, 2036 Taurine supplemented cell culture medium and methods of use
Claim Types: Process
Eylea (Injection) (Intravitreal)10961307 Sep 24, 2039 Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody
Claim Types: Method of use
Stelara (Injection) (Subcutaneous); Stelara (Injection) (Intravenous)10973879 May 17, 2039 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)10982003 Aug 6, 2030 Production of proteins in glutamine-free cell culture media
Claim Types: Process
Avastin (Injection) (Intravenous)10982003 Aug 11, 2029 Production of proteins in glutamine-free cell culture media
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)11008394 Dec 26, 2028 High concentration antibody-containing liquid formulation
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)11021728 Oct 25, 2030 Method for the production of a glycosylated immunoglobulin
Claim Types: Formulation
Actemra () (); Actemra (Injection) (Intravenous)11053280 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Eylea (Injection) (Intravitreal)11066458 Jun 14, 2027 VEGF antagonist formulations suitable for intravitreal administration
Claim Types: Drug in a container; Formulation
Eylea (Injection) (Intravitreal)11077404 May 13, 2035 Process control systems and methods for use with filters and filtration processes
Claim Types: Device; Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)11078294 Jul 8, 2028 Prevention of disulfide bond reduction during recombinant production of polypeptides
Claim Types: Process
Herceptin (For Injection) (Intravenous); Avastin (Injection) (Intravenous)11078294 Jul 9, 2027 Prevention of disulfide bond reduction during recombinant production of polypeptides
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)11083792 Apr 4, 2027 Purified antibody composition
Claim Types: Formulation claimed by its inherent performace characteristics
Humira (Injection) (Subcutaneous)11084865 Jun 14, 2027 VEGF antagonist formulations suitable for intravitreal administration
Claim Types: Drug in a container; Formulation
Eylea (Injection) (Intravitreal)11098079 Jul 21, 2037 Charged depth filtration of antigen-binding proteins
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)11104715 Aug 18, 2040 Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Claim Types: Process
Eylea (Injection) (Intravitreal)11124760 Aug 27, 2035 Methods for overcoming glutamine deprivation during mammalian cell culture
Claim Types: Process
Tysabri (Injection) (Intravenous)11130980 Apr 5, 2035 Use of monensin to regulate glycosylation of recombinant proteins
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)11136375 Oct 14, 2028 Method for production of antibody
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)11136610 Oct 25, 2030 Method for the production of a glycosylated immunoglobulin
Claim Types: Formulation; Product-by-process
Actemra () (); Actemra (Injection) (Intravenous)11160918 Jul 29, 2039 Medical device packaging and related methods
Claim Types: Kit
Eylea (Injection) (Intravitreal)11167030 Nov 28, 2028 Protein formulations and methods of making same
Claim Types: Formulation
Humira (Injection) (Subcutaneous)11174283 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Eylea (Injection) (Intravitreal)11186625 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Composition; Product-by-process
Eylea (Injection) (Intravitreal)11191834 Nov 28, 2028 Protein formulations and methods of making same
Claim Types: Formulation
Humira (Injection) (Subcutaneous)11253572 Jan 11, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use
Eylea (Injection) (Intravitreal)11254963 Dec 9, 2034 Increasing ornithine accumulation to increase high mannose glycoform content of recombinant proteins
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)11268119 Feb 21, 2036 Copper supplementation for control of glycosylation in mammalian cell culture process
Claim Types: Process
Tysabri (Injection) (Intravenous)11280794 May 27, 2034 Method of assessing risk of PML
Claim Types: Method of use
Tysabri (Injection) (Intravenous)11287423 Jan 11, 2031 Assay for JC virus antibodies
Claim Types: Formulation; Process
Tysabri (Injection) (Intravenous)11292845 Feb 28, 2027 Methods of treating inflammatory and autoimmune diseases with natalizumab
Claim Types: Method of use
Tysabri (Injection) (Intravenous)11299532 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Eylea (Injection) (Intravitreal)11299760 Oct 30, 2034 Use of monensin to regulate glycosylation of recombinant proteins
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)11306135 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Composition; Product-by-process
Eylea (Injection) (Intravitreal)11332771 Mar 14, 2034 Serum-free cell culture medium
Claim Types: Process
Eylea (Injection) (Intravitreal)11359026 Dec 26, 2028 High concentration antibody-containing liquid formulation
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)11377678 Oct 25, 2030 Method for the production of a glycosylated immunoglobulin
Claim Types: Process
Actemra () (); Actemra (Injection) (Intravenous)11433186 Dec 12, 2038 Devices and methods for precision dose delivery
Claim Types: Device; Process
Eylea (Injection) (Intravitreal)11434514 May 29, 2034 Methods for increasing mannose content of recombinant proteins
Claim Types: Process
Prolia (Injection) (Subcutaneous); Xgeva (Injection) (Subcutaneous)11439758 Jun 4, 2040 Devices and methods for precision dose delivery
Claim Types: Device
Eylea (Injection) (Intravitreal)11459373 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Eylea (Injection) (Intravitreal)11459374 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Eylea (Injection) (Intravitreal)11472861 Aug 18, 2040 Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
Claim Types: Process
Eylea (Injection) (Intravitreal)11478588 Jul 25, 2040 Needle shield grip devices and related methods
Claim Types: Device
Eylea (Injection) (Intravitreal)11485770 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Cell culture medium
Eylea (Injection) (Intravitreal)11505593 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Formulation; Drug in a container
Adcetris (For Injection) (Intravenous)11548932 Aug 18, 2040 Anti-VEGF protein compositions and methods for producing the same
Claim Types: Process
Bivigam (Injection) (Intravenous)11555176 Jan 27, 2040 Cell culture medium for eukaryotic cells
Claim Types: Process
Myalept (For Injection) (Subcutaneous)11559564 Jan 11, 2032 Use of a VEGF antagonist to treat angiogenic eye disorders
Claim Types: Method of use; Dosaage regimen
N/A (Injection) (Intravenous)11577025 Oct 6, 2037 Devices and methods for overfilling drug containers
Claim Types: Process
N/A (Injection) (Intravenous)11584798 Dec 26, 2028 High concentration antibody-containing liquid formulation
Claim Types: Formulation
Actemra () (); Actemra (Injection) (Intravenous)D858754 Sep 3, 2034 Syringe cap
Claim Types: Ornamental appearance of device or tablet
Eylea (Injection) (Intravitreal)D906102 Dec 29, 2035 Packaging
Claim Types: Ornamental appearance of device or tablet
Eylea (Injection) (Intravitreal)D934069 Oct 26, 2036 Packaging
Claim Types: Ornamental appearance of device or tablet
Eylea (Injection) (Intravitreal)D961376 Aug 23, 2037 Packaging
Claim Types: Ornamental appearance of device or tablet
Eylea (Injection) (Intravitreal)D961377 Aug 23, 2037 Packaging
Claim Types: Ornamental appearance of device or tablet
Eylea (Injection) (Intravitreal)